Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias

The American Journal of Cardiology
G R SimonsE L Pritchett

Abstract

This study assessed the cost effectiveness of inpatient antiarrhythmic therapy initiation for supraventricular tachycardias using a metaanalysis of proarrhythmic risk and a decision analysis that compared inpatient to outpatient therapy initiation. A MEDLINE search of trials of antiarrhythmic therapy for supraventricular tachycardias was performed, and episodes of cardiac arrest, sudden or unexplained death, syncope, and sustained or unstable ventricular arrhythmias were recorded. A weighted average event rate, by sample size, was calculated and applied to a clinical decision model of therapy initiation in which patients were either hospitalized for 72 hours or treated as outpatients. Fifty-seven drug trials involving 2,822 patients met study criteria. Based on a 72-hour weighted average event rate of 0.63% (95% confidence interval, 0.2% to 1.2%), inpatient therapy initiation cost $19,231 per year of life saved for a 60-year-old patient with a normal life expectancy. Hospitalization remained cost effective when event rates and life expectancies were varied to model hypothetical clinical scenarios. For example, cost-effectiveness ratios for a 40-year-old without structural heart disease and a 60-year-old with structural heart di...Continue Reading

References

Jul 23, 1992·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial II Investigators
Jul 15, 1992·Annals of Internal Medicine·R H Falk
Apr 1, 1991·International Journal of Cardiology·V KühlkampL Seipel
Jun 5, 1991·JAMA : the Journal of the American Medical Association·S E BedellT L Delbanco
Jan 1, 1991·European Journal of Clinical Pharmacology·H NakazawaK Ito
Jan 1, 1990·Circulation·M KuppermannJ N Ruskin
Jan 1, 1990·Cardiology·L Mary-Rabine, H E Kulbertus
Oct 1, 1990·Clinical Cardiology·C de Nooijer, C M Sparling
Jun 1, 1990·Cardiovascular Drugs and Therapy·R N Millar
Apr 1, 1990·International Journal of Cardiology·I VassiliadisC Stefanadis
Aug 10, 1989·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial (CAST) Investigators
Jun 1, 1989·Angiology·V SantinelliM Chiariello
Jan 1, 1989·The American Journal of Cardiology·J G Porterfield, L M Porterfield
Jun 1, 1987·The American Journal of Cardiology·E BernsG V Naccarelli
Jul 1, 1988·The American Journal of Cardiology·T H Marwick, S P Woodhouse
Apr 15, 1988·The American Journal of Cardiology·C R KerrJ C Cooper
Aug 4, 1988·The New England Journal of Medicine·J D MinardoE N Prystowsky
Oct 1, 1988·Journal of the American College of Cardiology·E M AntmanP L Friedman
Sep 1, 1972·British Heart Journal·G F Levi, C Proto
Mar 1, 1970·British Heart Journal·P SzekelyD A Sideris
Jan 1, 1968·British Heart Journal·M D Radford, D W Evans
May 1, 1966·British Heart Journal·P B Halmos
Apr 23, 1983·British Medical Journal·W S Hillis, B Whiting
Feb 1, 1984·British Heart Journal·J K McKibbinI W Obel
Sep 1, 1984·British Heart Journal·M J AntonaccioL F Soyka
Nov 24, 1983·The New England Journal of Medicine·J N RuskinE Kelly

❮ Previous
Next ❯

Citations

Dec 24, 2003·American Heart Journal·Jean-Yves Le HeuzeyLouis Guize
Apr 21, 1999·Journal of Cardiovascular Electrophysiology·R J MyerburgA Castellanos
Aug 10, 2002·Current Cardiology Reports·Gerald V NaccarelliJerry Luck
May 24, 2000·The American Journal of Cardiology·E N Prystowsky
May 7, 2009·The Annals of Pharmacotherapy·Michael H KimDavid S Battleman
Jun 16, 2005·Home Healthcare Nurse·Patricia J Neafsey
Sep 4, 2004·PharmacoEconomics·M P TengD P Melby

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.